Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Eli Lilly and Company

This publication has 36 references indexed in Scilit: